Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314377 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab Therapy for Brain Arteriovenous Malformation
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02314377: Completed Phase 1 study, sponsored by University of California, San Francisco.
NCT02314377 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02314377, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Bevacizumab Therapy for brain arteriovenous malformation that is not amenable to surgical intervention.
Primary Outcome
AVM volume will be assessed by review of standardized 1.5 mm slices in the axial plane. The contour of the vascular mass using time-of-flight MR angiography sequences will generate a cross-sectional area at each slice level. The volume will be estimated by summing the imputed volume of each slice. This is the standard method in radiation oncology used to assess bAVM volume for radiosurgery treatment planning using commercial software (Leksell GammaPlan). The source images and measurement images
Interventions
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 1 |
What the finished NCT02314377 record still lists
NCT02314377 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab is the first listed.
NCT02314377 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02314377 about?
NCT02314377 is a clinical study titled "Bevacizumab Therapy for Brain Arteriovenous Malformation". Bevacizumab Therapy for brain arteriovenous malformation that is not amenable to surgical intervention.
What is the current status of trial NCT02314377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-06. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT02314377?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT02314377?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02314377's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia